Unum Therapeutics Inc (NASDAQ:UMRX) shares hit a new 52-week low during trading on Thursday . The company traded as low as $6.18 and last traded at $6.46, with a volume of 4116 shares traded. The stock had previously closed at $6.65.
UMRX has been the topic of a number of recent research reports. Zacks Investment Research upgraded Unum Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 30th. Morgan Stanley boosted their price objective on Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research note on Monday, November 19th. Finally, Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Unum Therapeutics in a research note on Tuesday, September 18th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $20.67.
Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings data on Monday, November 12th. The company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.01. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.29 million. Unum Therapeutics had a negative return on equity of 382.71% and a negative net margin of 404.34%. On average, equities analysts predict that Unum Therapeutics Inc will post -1.56 EPS for the current fiscal year.
In other Unum Therapeutics news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Thursday, October 25th. The stock was sold at an average price of $8.46, for a total transaction of $97,163.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 34,455 shares of company stock worth $320,776.
Institutional investors and hedge funds have recently modified their holdings of the business. Jennison Associates LLC lifted its stake in shares of Unum Therapeutics by 4.3% in the second quarter. Jennison Associates LLC now owns 935,307 shares of the company’s stock worth $13,305,000 after acquiring an additional 38,552 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Unum Therapeutics in the second quarter worth about $177,000. Spark Investment Management LLC acquired a new position in shares of Unum Therapeutics in the second quarter worth about $186,000. Keybank National Association OH acquired a new position in shares of Unum Therapeutics in the second quarter worth about $195,000. Finally, BlackRock Inc. acquired a new position in shares of Unum Therapeutics in the second quarter worth about $6,403,000. Institutional investors own 51.07% of the company’s stock.
WARNING: This report was first reported by Equities Focus and is owned by of Equities Focus. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.equitiesfocus.com/2018/12/08/unum-therapeutics-umrx-reaches-new-12-month-low-at-6-18.html.
Unum Therapeutics Company Profile (NASDAQ:UMRX)
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Featured Article: What is intrinsic value?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.